Kanada - francoščina - Health Canada

novopharm limited - chlorhydrate de doxorubicine - solution - 2mg - chlorhydrate de doxorubicine 2mg - antineoplastic agents

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - fumarate d'hydrogène de kétotifène 0,276 mg/ml - eq. kétotifène 0,201 mg/ml - sirop - 1 mg/5 ml - fumarate d'hydrogène de kétotifène 0.276 mg/ml - ketotifen

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen sa-nv - ginkgo biloba, extrait 40 mg/ml - solution buvable - 40 mg/dose - ginkgo biloba, extrait 40 mg/ml - ginkgo folium

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen consumer healthcare - ginkgo biloba l., feuille, extrait sec acétonique 60 35-67_1egb 761 40 mg - comprimé enrobé - 40 mg - ginkgo biloba, extrait 40 mg - ginkgo folium

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alfasigma s.p.a. - fumarate d'hydrogène de kétotifène 1,38 mg - eq. kétotifène 1 mg - gélule - 1 mg - fumarate d'hydrogène de kétotifène 1.38 mg - ketotifen

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alfasigma s.p.a. - fumarate d'hydrogène de kétotifène 0,276 mg/ml - eq. kétotifène 0,2 mg/ml - sirop - 1 mg/5 ml - fumarate d'hydrogène de kétotifène 0.276 mg/ml - ketotifen

Belgija - francoščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alfasigma s.p.a. - fumarate d'hydrogène de kétotifène 2,75 mg - eq. kétotifène 2 mg - comprimé à libération prolongée - 2 mg - fumarate d'hydrogène de kétotifène 2.75 mg - ketotifen

Kanada - francoščina - Health Canada

boehringer ingelheim animal health canada inc. - ciclésonide - solution - 343mcg - ciclésonide 343mcg - chevaux

Evropska unija - francoščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agents antinéoplasiques - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. pour plus d'informations sur le statut du récepteur du facteur de croissance épidermique humain 2 (her2), veuillez vous référer à la section 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. pour plus d'informations sur le statut her2, veuillez vous référer à la section 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Evropska unija - francoščina - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agents antinéoplasiques - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. pour plus d'informations sur le statut du récepteur du facteur de croissance épidermique humain 2 (her2), veuillez vous référer à la section 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. pour plus d'informations sur le statut her2, veuillez vous référer à la section 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.